1. Home
  2. FATE vs NHS Comparison

FATE vs NHS Comparison

Compare FATE & NHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fate Therapeutics Inc.

FATE

Fate Therapeutics Inc.

N/A

Current Price

$1.29

Market Cap

260.0M

Sector

Health Care

ML Signal

N/A

Logo Neuberger Berman High Yield Strategies Fund

NHS

Neuberger Berman High Yield Strategies Fund

N/A

Current Price

$5.53

Market Cap

251.6M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
FATE
NHS
Founded
2007
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
260.0M
251.6M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
FATE
NHS
Price
$1.29
$5.53
Analyst Decision
Buy
Analyst Count
11
0
Target Price
★ $5.72
N/A
AVG Volume (30 Days)
★ 1.5M
258.4K
Earning Date
11-05-2026
01-01-0001
Dividend Yield
N/A
★ 13.44%
EPS Growth
★ 29.88
N/A
EPS
N/A
★ N/A
Revenue
★ $6,646,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$18.72
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.95
$5.26
52 Week High
$3.23
$7.75

Technical Indicators

Market Signals
Indicator
FATE
NHS
Relative Strength Index (RSI) 23.18 50.13
Support Level $1.07 $5.26
Resistance Level $1.38 $6.12
Average True Range (ATR) 0.16 0.07
MACD -0.07 0.01
Stochastic Oscillator 7.35 56.06

Price Performance

Historical Comparison
FATE
NHS

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

About NHS Neuberger Berman High Yield Strategies Fund

Neuberger Berman High Yield Strategies Fund Inc is a diversified, closed-end management investment company. The company invests in high yield debt securities market. The Fund uses leverage to pursue its investment objective. The Fund may invest in a variety of direct debt instruments, including bank loans, notes and other interests in amounts owed to financial institutions by borrowers, such as companies and governments. Corporate loans in which the Fund may invest will consist of direct obligations of borrowers. The Fund may invest in corporate loans at origination as a co-lender or may acquire loans in the secondary market by purchasing participations in, assignments of or novations of corporate loans.

Share on Social Networks: